New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - ciprofloxacin hydrochloride 277.5mg equivalent to ciprofloxacin 250 mg (anhydrous);   - film coated tablet - 250 mg - active: ciprofloxacin hydrochloride 277.5mg equivalent to ciprofloxacin 250 mg (anhydrous)   excipient: colloidal silicon dioxide crospovidone hypromellose macrogols magnesium stearate maize starch microcrystalline cellulose opadry white y-22-7719 polydextrose pregelatinised maize starch purified water titanium dioxide triacetin - for complicated urinary tract infections or pyelonephritis due to e.coli in paediatric patients aged 1-17 years. the risk-benefit assessment indicates that administration of ciprofloxacin to paediatric patients is appropriate. treatment should only be initiated after careful benefit/risk evaluation, due to possible adverse events related to joints/surrounding tissues. the use of ciprofloxacin for other indications is not recommended in children.

Singapore - English - HSA (Health Sciences Authority)

glaxosmithkline pte ltd - levetiracetam - tablet, film coated - 250 mg - levetiracetam 250 mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - naproxen - oral tablet - 250mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

phoenix healthcare distribution ltd - naproxen - oral tablet - 250mg

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

genesis pharmaceuticals ltd - naproxen - oral tablet - 250mg

Australia - English - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - naproxen, quantity: 250 mg - tablet, uncoated - excipient ingredients: croscarmellose sodium; iron oxide yellow; povidone; magnesium stearate - for the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, symptomatic treatment of primary dysmenorrhoea, for the relief of acute and/or chronic pain states in which there is an inflammatory component and as an analgesic in acute migraine attack.

Australia - English - Department of Health (Therapeutic Goods Administration)

atnahs pharma australia pty ltd - famciclovir, quantity: 250 mg - tablet, film coated - excipient ingredients: magnesium stearate; hyprolose; lactose; sodium starch glycollate; titanium dioxide; hypromellose; macrogol 6000; macrogol 4000 - elovax is indicated for the treatment of herpes zoster infection in adult patients who commence therapy within 72 hours of the onset of the rash. greatest benefit occurs if the drug is started within 48 hours. efficacy has not been demonstrated in patients less than 50 years of age, although the occasional younger patient with severe herpes zoster may benefit from therapy with famciclovir. herpes zoster is generally a milder condition in younger patients. elovax is also indicated in the treatment of recurrent episodes of genital herpes in adults and adolescents 12 years of age and older. elovax is also indicated for suppression of recurrent genital herpes. elovax is also indicated for the treatment of recurrent herpes labialis (cold sores) in immunocompetent patients elovax is also indicated in immunocompromised patients for: treatment of uncomplicated herpes zoster; treatment of recurrent herpes simplex; suppression of recurrent herpes simplex.

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - famciclovir, quantity: 250 mg - tablet, film coated - excipient ingredients: sodium starch glycollate; microcrystalline cellulose; hyprolose; magnesium stearate; titanium dioxide; purified talc; polyvinyl alcohol; macrogol 3350 - favic is indicated for the treatment of herpes zoster infection in adult patients who commence therapy within 72 hours of the onset of rash. greatest benefit occurs if the drug is started within 48 hours. efficacy has not been demonstrated in patients less than 50 years of age, although the occasional younger patient with severe herpes zoster may benefit from therapy with famciclovir. herpes zoster infection is generally a milder condition in younger patients. favic is also indicated for the treatment of recurrent episodes of genital herpes in adults and adolescents 12 years of age and older. favic is also indicated for suppression of recurrent genital herpes. favic is also indicated for the treatment of recurrent herpes labialis (cold sores) in immunocompetent adult patients. favic is also indicated in immunocompromised patients for: - treatment of uncomplicated herpes zoster. - treatment of recurrent herpes simplex. - suppression of recurrent herpes simplex.

Australia - English - Department of Health (Therapeutic Goods Administration)

viatris pty ltd - temozolomide, quantity: 250 mg - capsule, hard - excipient ingredients: purified water; tartaric acid; stearic acid; lactose; sodium starch glycollate; gelatin; colloidal anhydrous silica; sodium lauryl sulfate; titanium dioxide; propylene glycol; ethanol; butan-1-ol; isopropyl alcohol; shellac; strong ammonia solution; iron oxide black; potassium hydroxide - treatment of newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as adjuvant treatment.,treatment of recurrence of anaplastic astrocytoma and glioblastoma multiforme following standard therapy.,temozolomide is also indicated as a first-line treatment for patients with advanced metastatic malignant melanoma.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - fluticasone propionate 40mg equivalent to 250 µg/dose;  ; salmeterol xinafoate 5.8mg equivalent to 25 µg/dose salmeterol;   - aerosol inhaler, metered dose - 250µg/25µg - active: fluticasone propionate 40mg equivalent to 250 µg/dose   salmeterol xinafoate 5.8mg equivalent to 25 µg/dose salmeterol   excipient: norflurane - seretide is indicated in the regular treatment of reversible obstructive airways disease (road), including asthma in children and adults, where use of a combination (bronchodilator and inhaled corticosteroid) is appropriate. this may include: patients on effective maintenance doses of long-acting ?-agonists and inhaled corticosteroids. patients who are symptomatic on current inhaled corticosteroid therapy. patients who are symptomatic on "as needed" short-acting betaagonists, as an alternative to initiation of maintenance therapy with moderate or high doses of inhaled corticosteroid alone.